Wet Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems
Tan Tock Seng Hospital is conducting a user-centric study to assess patients' receptiveness to a web-based automated gaze-tracking analysis …
-
EMA approval · 2026-01-09EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients
A clinical trial update on automated vision assessment and impairment detection using gaze analysis in patients with age-related macular deg…
-
EMA approval · 2026-01-06EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
The EMA authorised Vabysmo (faricimab) by Roche Registration GmbH for treatment of wet age-related macular degeneration, macular edema, and …
-
EMA approval · 2025-12-17EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited
EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, dia…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration [Phase 3]
Phase 3 efficacy evaluation comparing BAT5906 to Lucentis in neovascular age-related macular degeneration has completed, with efficacy data …
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD [NA]
This clinical trial compares rapid aflibercept versus brolucizumab with a treat-and-extend approach in wet age-related macular degeneration …
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration [Phase 3]
A Phase 3 study evaluating efficacy and safety of Ixoberogene Soroparvovec (Ixo-vec) for neovascular age-related macular degeneration is cur…
-
EMA approval · 2025-11-14EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH
Epruvy, a new marketed form of ranibizumab by Midas Pharma, has been authorised for treating wet age-related macular degeneration, macular e…
-
EMA approval · 2025-11-14EMA Authorised: Ranivisio (ranibizumab) — Midas Pharma GmbH
The EMA authorised Ranivisio (ranibizumab) for ocular indications including wet age-related macular degeneration, macular edema, and diabeti…
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK [Phase 3]
Phase 3 DAYBREAK trial evaluating the efficacy and safety of two investigational agents (Tarcocimab Tedromer and Tabirafusp Tedromer) agains…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) [Phase 2]
The Phase 2 study of EYP-1901 in wet age-related macular degeneration has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) [Phase 1, Phase 2]
This document reports a Phase 1/2 clinical trial evaluating the safety and efficacy of oral HX9428 tablets in patients with wet age-related …
-
CLINICAL_TRIALS trial_result · 2025-09-09Clinical Trial Update: Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops [Phase 1]
This is a Phase 1 study evaluating the safety and tolerability of SCAI-005 Eye Drops for Wet Age-Related Macular Degeneration. The trial sta…
-
FDA approval · 2025-09-05FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for SUSVIMO, a port delivery system delivering ranibizumab, for treatment of wet age-related macular…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) [Phase 3]
Phase 3 trial HEIRLOOM evaluating high-dose aflibercept switching (load vs maintain) for wet/neovascular age-related macular degeneration.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: A Long-term Follow up Study of EXG102-031 in Participants With wAMD
A long-term follow-up study of EXG102-031 for wet age-related macular degeneration is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: Optimizing the Treatment Strategy for Age-related Macular Degeneration [NA]
This clinical trial update discusses optimizing treatment strategies for wet age-related macular degeneration. The trial is currently active…